Report of Foreign Issuer (6-k)
July 05 2019 - 9:01AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the month of: July 2019
|
|
Commission File Number: 001-35776
|
ACASTI PHARMA INC.
(Name of Registrant)
545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office
)
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
¨
On July 3, 2019, Acasti Pharma Inc. (the “Corporation”) received written
notification from the Listing Qualifications Department of The Nasdaq Stock Market that the Corporation regained compliance with
Listing Rule 5550(a)(2), which requires a minimum bid price of U.S.$1.00 per share. The Corporation is now fully compliant with
Nasdaq’s minimum bid rules and this matter is now closed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
ACASTI PHARMA INC.
|
Date: July 5, 2019
|
By:
|
/s/ Jan D'Alvise
|
|
|
Name: Jan D'Alvise
Title: Chief Executive Officer
|
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Apr 2023 to Apr 2024